Get the Stockscreener App
9.86
0.69%
-0.03
Novavax Inc stock is traded at $9.86, with a volume of 961.07K.
It is down -0.69% in the last 24 hours and up +24.80% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$9.89
Open:
$9.56
24h Volume:
961.07K
Relative Volume:
0.21
Market Cap:
$1.60B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
4.3246
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-12.23%
1M Performance:
+24.80%
6M Performance:
+24.33%
1Y Performance:
+24.49%
1-Day Range:
$9.55
$9.87
1-Week Range:
$9.1394
$11.15
52-Week Range:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.86 | 1.61B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.95 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.60 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
NVAX: HC Wainwright & Co. Raises Price Target Amidst Buy Rating - GuruFocus
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Zacks Investment Research
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook - Finviz
Novavax to Participate in Upcoming Investor Conferences - Sahm
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax Q4 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS - MarketBeat
What's Going On With Novavax Stock On Friday? - Bitget
NVV1.F Novavax, Inc. (XETRA) up 15.65% pre-market 27 Feb 2026: earnings catalyst - Meyka
Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Novavax (NVAX) Turns Profitable With US$440 Million TTM Net Income Challenging Bearish Views - simplywall.st
Novavax raises revenue forecast on boost from vaccine deals, shares soar - marketscreener.com
Novavax faces investor questions at three March healthcare events - Stock Titan
Novavax jumps as Q4 profit, higher revenue, and partnership milestones highlight a pivot to licensing - Quiver Quantitative
Novavax (NVAX) Reports Strong Q4 2025 Revenue Growth and Strategic Partnerships - GuruFocus
Novavax outlook 2026 adjusted total revenue $230 mln$270 mln - marketscreener.com
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals - marketscreener.com
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb - Benzinga
Why Is Novavax (NVAX) Stock Soaring Today - Yahoo Finance
Novavax’s stock soars on expected revenue jump from big pharma deals - The Business Journals
Novavax Q4 2025 slides: earnings beat fuels partnership transformation - Investing.com
Novavax Q4 2025 slides: earnings beat fuels partnership transformation By Investing.com - Investing.com South Africa
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Sees Unusually High Options Volume (NASDAQ:NVAX) - MarketBeat
Earnings call transcript: Novavax Q4 2025 earnings beat expectations, stock rises - Investing.com India
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
59,600 |
0 |
111,706 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
4,000 |
0 |
65,159 |
| Jacobs John C | President and CEO |
Jan 23 '26 |
Option Exercise |
0.00 |
83,197 |
0 |
219,929 |
| Casey Mark J | EVP, Chief Legal Officer |
Dec 11 '25 |
Option Exercise |
0.00 |
41,899 |
0 |
73,972 |
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):